Инд. авторы:	Obut T.A., Ovsyukova M.V., Egorova S.A., Erdynieva T.A., Dementeva T.Yu., Obut E.T., Gorobchuk A.G.
Заглавие:	Hypotensive effect of retabolil correcting the concentration of aldosterone during stress exposures
Библ. ссылка:	Obut T.A., Ovsyukova M.V., Egorova S.A., Erdynieva T.A., Dementeva T.Yu., Obut E.T., Gorobchuk A.G. Hypotensive effect of retabolil correcting the concentration of aldosterone during stress exposures // Bulletin of Experimental Biology and Medicine. - 2014. - Vol.157. - Iss. 2. - P.231-233. - ISSN 0007-4888. - EISSN 1573-8221.
Внешние системы:	DOI: 10.1007/s10517-014-2532-y; РИНЦ: 22775254; WoS: 000339005200014;
Реферат:	eng: Male rats were exposed to single or repeated (19 days) cold treatment (4°C) and non-cold stress (60-min shaking on a laboratory shuttle device). Retabolil had a hypotensive effect, which was accompanied by the prevention of a stress-induced increase in the concentration of a hypertensive hormone aldosterone. Under conditions of repeated stress, these effects were realized via μ-opioid receptors. Our results suggest that retabolil can be used as a hypotensive and aldosterone-blocking agent, at least during stress exposure in animals (and probably in humans).
Ключевые слова:	retabolil aldosterone blood pressure stress exposures μ-opioid receptors;
Издано:	2014
Физ. характеристика:	с.231-233
Цитирование:	1. L. A. Leshchinskii, V. G. Lazarenko, and I. A. Shinkareva, Kardiologiya, 16, No. 1, 48-53 (1976). 2. T. A. Obut, Androgens in Adaptation of the Body: Biological Signifi cance of Adrenal Androgens , Novosibirsk (2004). 3. T. A. Obut, Byull. Sib. Otd. Ros. Akad. Med. Nauk, 14, No. 2, 62-68 (1994). 4. M. V. Ovsyukova and T. A. Obut, Physiological Effects of Dehydroepiandrosterone Sulfate via μ-Opioid Receptors , Novosibirsk (2011). 5. T. A. Obut, E. T. Obut, and A. L. Markel`, Patent RF No. 2142802, Hypotensive Drug, Byull. Izobret., No. 9 (December 20, 1999). 6. R. G. Segal`, E. I. Zharov, and P. M. Savenkov, Kardiologiya, 10, No. 2, 24-30 (1970). 7. P. O. Cover and J. C. Buckingham, J. Endocrinol., 121, No. 2, 213-220 (1989). 8. R. Francesconi and M. Mager, Experientia, 39, No. 6, 581-583 (1983). 9. E. M. Freel and J. M. C. Connell, J. Am. Soc. Nephrol., 15, No. 8, 1993-2001 (2004). 10. K. Hiramatsu, T. Yamada, and M. Katakura, Clin. Exp. Pharmacol. Physiol., 11, No. 2, 171-179 (1984). 11. N. Maninger, O. M. Wolkowitz, V. I. Reus, et al., Front. Neuroendocrinol., 30, No. 1, 65-91 (2009). 12. O. T. Wolf and C. Kirshbaum, Brain Res. Brain Res. Rev., 30, No. 3, 264-288 (1999).